Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy—the P-SELECT trial (WJOG10617G)—a randomised phase II trial by the West Japan Oncology Group

BACKGROUND: Ramucirumab (RAM) with weekly paclitaxel (wPTX) is a standard second-line therapy for advanced or recurrent gastric cancer. Nanoparticle albumin-bound paclitaxel (nab-PTX), an albumin-bound form of PTX, was developed to improve the therapeutic index of taxane treatment. However, the ABSO...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirata, Kenro, Hamamoto, Yasuo, Ando, Masahiko, Imamura, Chiyo K., Yoshimura, Kenichi, Yamazaki, Kentaro, Hironaka, Shuichi, Muro, Kei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291575/
https://www.ncbi.nlm.nih.gov/pubmed/32532230
http://dx.doi.org/10.1186/s12885-020-07047-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291575/
https://www.ncbi.nlm.nih.gov/pubmed/32532230
http://dx.doi.org/10.1186/s12885-020-07047-1

Ejemplares similares